BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma

Samantha L. Kendrick, Lucas Redd, Andrea Muranyi, Leigh A. Henricksen, Stacey Stanislaw, Lynette M. Smith, Anamarija M. Perry, Kai Fu, Dennis D. Weisenburger, Andreas Rosenwald, German Ott, Randy D. Gascoyne, Elaine S. Jaffe, Elías Campo, Jan Delabie, Rita Braziel, James R. Cook, Raymond R. Tubbs, Louis M. Staudt, Wing Chung ChanChristian Steidl, Thomas M. Grogan, Lisa M. Rimsza

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Patients with aggressive, BCL2 protein-positive (+) diffuse large B-cell lymphoma (DLBCL) often experience rapid disease progression that is refractory to standard therapy. However, there is potential for false-negative staining of BCL2 using the standard monoclonal mouse 124 antibody that hinders the identification of these high-risk DLBCL patients. Herein, we compare 2 alternative rabbit monoclonal antibodies (E17 and SP66) to the 124 clone in staining for BCL2 in formalin-fixed, paraffin-embedded DLBCL tissues. Overall, in 2 independent DLBCL cohorts, E17 and SP66 detected BCL2 expression more frequently than 124. In the context of MYC expression, cases identified as BCL2 (+) with SP66 demonstrated the strongest correlation with worse overall survival. The 124 clone failed to detect BCL2 expression in the majority of translocation (+), amplification (+), and activated B-cell DLBCL cases in which high levels of BCL2 protein are expected. Using dual in situ hybridization as a new tool to detect BCL2 translocation and amplification, we observed similar results as previously reported for fluorescence in situ hybridization for translocation but a higher amplification frequency, indicating that BCL2 amplification may be underreported in DLBCL. Among the discrepant cases, phosphorylation of BCL2 at T69 and/or S70 was more common than in the concordant cases and may contribute to the 124 false negatives, in addition to previously associated mutations within the epitope region. The accurate detection of BCL2 expression is important in the prognosis and treatment of DLBCL particularly with new anti-BCL2 therapies.

Original languageEnglish (US)
Pages (from-to)2144-2153
Number of pages10
JournalHuman Pathology
Volume45
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Gene Amplification
Epitopes
Antibodies
Proto-Oncogene Proteins c-bcl-2
Proteins
Clone Cells
Negative Staining
Fluorescence In Situ Hybridization
Paraffin
Formaldehyde
In Situ Hybridization
Disease Progression
B-Lymphocytes
Therapeutics
Monoclonal Antibodies
Phosphorylation
Staining and Labeling
Rabbits
Mutation

Keywords

  • BCL2 amplification and translocation
  • BCL2 phosphorylation
  • Diffuse large B-cell lymphoma
  • Dual in situ hybridization (dual ISH)
  • E17 and SP66 BCL2 antibodies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. / Kendrick, Samantha L.; Redd, Lucas; Muranyi, Andrea; Henricksen, Leigh A.; Stanislaw, Stacey; Smith, Lynette M.; Perry, Anamarija M.; Fu, Kai; Weisenburger, Dennis D.; Rosenwald, Andreas; Ott, German; Gascoyne, Randy D.; Jaffe, Elaine S.; Campo, Elías; Delabie, Jan; Braziel, Rita; Cook, James R.; Tubbs, Raymond R.; Staudt, Louis M.; Chan, Wing Chung; Steidl, Christian; Grogan, Thomas M.; Rimsza, Lisa M.

In: Human Pathology, Vol. 45, No. 10, 01.10.2014, p. 2144-2153.

Research output: Contribution to journalArticle

Kendrick, SL, Redd, L, Muranyi, A, Henricksen, LA, Stanislaw, S, Smith, LM, Perry, AM, Fu, K, Weisenburger, DD, Rosenwald, A, Ott, G, Gascoyne, RD, Jaffe, ES, Campo, E, Delabie, J, Braziel, R, Cook, JR, Tubbs, RR, Staudt, LM, Chan, WC, Steidl, C, Grogan, TM & Rimsza, LM 2014, 'BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma', Human Pathology, vol. 45, no. 10, pp. 2144-2153. https://doi.org/10.1016/j.humpath.2014.06.005
Kendrick, Samantha L. ; Redd, Lucas ; Muranyi, Andrea ; Henricksen, Leigh A. ; Stanislaw, Stacey ; Smith, Lynette M. ; Perry, Anamarija M. ; Fu, Kai ; Weisenburger, Dennis D. ; Rosenwald, Andreas ; Ott, German ; Gascoyne, Randy D. ; Jaffe, Elaine S. ; Campo, Elías ; Delabie, Jan ; Braziel, Rita ; Cook, James R. ; Tubbs, Raymond R. ; Staudt, Louis M. ; Chan, Wing Chung ; Steidl, Christian ; Grogan, Thomas M. ; Rimsza, Lisa M. / BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. In: Human Pathology. 2014 ; Vol. 45, No. 10. pp. 2144-2153.
@article{092511e3620442aebe3b51f21fbe9157,
title = "BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma",
abstract = "Patients with aggressive, BCL2 protein-positive (+) diffuse large B-cell lymphoma (DLBCL) often experience rapid disease progression that is refractory to standard therapy. However, there is potential for false-negative staining of BCL2 using the standard monoclonal mouse 124 antibody that hinders the identification of these high-risk DLBCL patients. Herein, we compare 2 alternative rabbit monoclonal antibodies (E17 and SP66) to the 124 clone in staining for BCL2 in formalin-fixed, paraffin-embedded DLBCL tissues. Overall, in 2 independent DLBCL cohorts, E17 and SP66 detected BCL2 expression more frequently than 124. In the context of MYC expression, cases identified as BCL2 (+) with SP66 demonstrated the strongest correlation with worse overall survival. The 124 clone failed to detect BCL2 expression in the majority of translocation (+), amplification (+), and activated B-cell DLBCL cases in which high levels of BCL2 protein are expected. Using dual in situ hybridization as a new tool to detect BCL2 translocation and amplification, we observed similar results as previously reported for fluorescence in situ hybridization for translocation but a higher amplification frequency, indicating that BCL2 amplification may be underreported in DLBCL. Among the discrepant cases, phosphorylation of BCL2 at T69 and/or S70 was more common than in the concordant cases and may contribute to the 124 false negatives, in addition to previously associated mutations within the epitope region. The accurate detection of BCL2 expression is important in the prognosis and treatment of DLBCL particularly with new anti-BCL2 therapies.",
keywords = "BCL2 amplification and translocation, BCL2 phosphorylation, Diffuse large B-cell lymphoma, Dual in situ hybridization (dual ISH), E17 and SP66 BCL2 antibodies",
author = "Kendrick, {Samantha L.} and Lucas Redd and Andrea Muranyi and Henricksen, {Leigh A.} and Stacey Stanislaw and Smith, {Lynette M.} and Perry, {Anamarija M.} and Kai Fu and Weisenburger, {Dennis D.} and Andreas Rosenwald and German Ott and Gascoyne, {Randy D.} and Jaffe, {Elaine S.} and El{\'i}as Campo and Jan Delabie and Rita Braziel and Cook, {James R.} and Tubbs, {Raymond R.} and Staudt, {Louis M.} and Chan, {Wing Chung} and Christian Steidl and Grogan, {Thomas M.} and Rimsza, {Lisa M.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2014.06.005",
language = "English (US)",
volume = "45",
pages = "2144--2153",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma

AU - Kendrick, Samantha L.

AU - Redd, Lucas

AU - Muranyi, Andrea

AU - Henricksen, Leigh A.

AU - Stanislaw, Stacey

AU - Smith, Lynette M.

AU - Perry, Anamarija M.

AU - Fu, Kai

AU - Weisenburger, Dennis D.

AU - Rosenwald, Andreas

AU - Ott, German

AU - Gascoyne, Randy D.

AU - Jaffe, Elaine S.

AU - Campo, Elías

AU - Delabie, Jan

AU - Braziel, Rita

AU - Cook, James R.

AU - Tubbs, Raymond R.

AU - Staudt, Louis M.

AU - Chan, Wing Chung

AU - Steidl, Christian

AU - Grogan, Thomas M.

AU - Rimsza, Lisa M.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Patients with aggressive, BCL2 protein-positive (+) diffuse large B-cell lymphoma (DLBCL) often experience rapid disease progression that is refractory to standard therapy. However, there is potential for false-negative staining of BCL2 using the standard monoclonal mouse 124 antibody that hinders the identification of these high-risk DLBCL patients. Herein, we compare 2 alternative rabbit monoclonal antibodies (E17 and SP66) to the 124 clone in staining for BCL2 in formalin-fixed, paraffin-embedded DLBCL tissues. Overall, in 2 independent DLBCL cohorts, E17 and SP66 detected BCL2 expression more frequently than 124. In the context of MYC expression, cases identified as BCL2 (+) with SP66 demonstrated the strongest correlation with worse overall survival. The 124 clone failed to detect BCL2 expression in the majority of translocation (+), amplification (+), and activated B-cell DLBCL cases in which high levels of BCL2 protein are expected. Using dual in situ hybridization as a new tool to detect BCL2 translocation and amplification, we observed similar results as previously reported for fluorescence in situ hybridization for translocation but a higher amplification frequency, indicating that BCL2 amplification may be underreported in DLBCL. Among the discrepant cases, phosphorylation of BCL2 at T69 and/or S70 was more common than in the concordant cases and may contribute to the 124 false negatives, in addition to previously associated mutations within the epitope region. The accurate detection of BCL2 expression is important in the prognosis and treatment of DLBCL particularly with new anti-BCL2 therapies.

AB - Patients with aggressive, BCL2 protein-positive (+) diffuse large B-cell lymphoma (DLBCL) often experience rapid disease progression that is refractory to standard therapy. However, there is potential for false-negative staining of BCL2 using the standard monoclonal mouse 124 antibody that hinders the identification of these high-risk DLBCL patients. Herein, we compare 2 alternative rabbit monoclonal antibodies (E17 and SP66) to the 124 clone in staining for BCL2 in formalin-fixed, paraffin-embedded DLBCL tissues. Overall, in 2 independent DLBCL cohorts, E17 and SP66 detected BCL2 expression more frequently than 124. In the context of MYC expression, cases identified as BCL2 (+) with SP66 demonstrated the strongest correlation with worse overall survival. The 124 clone failed to detect BCL2 expression in the majority of translocation (+), amplification (+), and activated B-cell DLBCL cases in which high levels of BCL2 protein are expected. Using dual in situ hybridization as a new tool to detect BCL2 translocation and amplification, we observed similar results as previously reported for fluorescence in situ hybridization for translocation but a higher amplification frequency, indicating that BCL2 amplification may be underreported in DLBCL. Among the discrepant cases, phosphorylation of BCL2 at T69 and/or S70 was more common than in the concordant cases and may contribute to the 124 false negatives, in addition to previously associated mutations within the epitope region. The accurate detection of BCL2 expression is important in the prognosis and treatment of DLBCL particularly with new anti-BCL2 therapies.

KW - BCL2 amplification and translocation

KW - BCL2 phosphorylation

KW - Diffuse large B-cell lymphoma

KW - Dual in situ hybridization (dual ISH)

KW - E17 and SP66 BCL2 antibodies

UR - http://www.scopus.com/inward/record.url?scp=84908159321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908159321&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2014.06.005

DO - 10.1016/j.humpath.2014.06.005

M3 - Article

C2 - 25090918

AN - SCOPUS:84908159321

VL - 45

SP - 2144

EP - 2153

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -